8-K Announcements
6Material company update
Feb 20, 2026·SEC
Material company update
Feb 11, 2026·SEC
Material company update
Feb 3, 2026·SEC
Abpro Holdings Inc(ABPWW)Earnings, Financials & Key Ratios
ABPWW•NASDAQ
$0.00
Price updated Jun 27, 2026
AboutAbpro Holdings, Inc., a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues. Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry. Its lead product candidates include ABP-100 for the treatment of breast, gastric, and colorectal cancers; and ABP-201 for the treatment of vascular diseases of the eye. The company has a strategic partnership with Abpro Bio Co. Ltd and NJCTTQ. The company was formerly known as Abpro Corporation and changed its name to Abpro Holdings, Inc. in November 2024. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.Show more
- Revenue$0-100.0%
- EBITDA-$8M+13.8%
- Net Income-$3M+60.0%
- EPS (Diluted)-1.30+94.4%
- ROE-526.78%
ABPWW Price & Volume
Abpro Holdings Inc (ABPWW) stock price & volume — 10-year historical chart
Loading chart...
Abpro Holdings Faces Critical Liquidity Insolvency Risk
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Immediate liquidity insolvency risk
"Abpro Holdings operates as a pre-revenue clinical-stage biotechnology firm with a business model entirely dependent on sporadic milestone payments, lacking any recurring revenue foundation. The company's financial trajectory is characterized by persistent operating losses, with quarterly deficits frequently exceeding $1 million, which severely limits its ability to advance the DiversImmune platform. Investors should exercise extreme caution given the firm's precarious liquidity position and the potential for highly dilutive financing required to sustain ongoing operations."
Verdict Logic
the company faces an existential liquidity crisis with cash reserves falling to as low as $67,000, rendering the current capital structure insufficient to support long-term clinical development.
ABPWW Growth Metrics
Abpro Holdings Inc (ABPWW) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-24.95%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM80.36%
Return on Capital
10 Years-238.31%
5 Years-462.16%
3 Years-
Last Year-
Peers Comparison
Key metrics vs top competitors for Abpro Holdings Inc (ABPWW)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.00 | $11.23M | -0.00 | -100% | — | -526.78% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $31.00 | $3.12B | -9.42 | -4.26% | -156.36% | -68.97% | — | |
| $3.03 | $126.18M | -891.18 | 10.37% | 52.16% | — | — | |
| $4.81 | $305.74M | -4.08 | 0.78% | -44.79% | -147.8% | — | |
| $15.05 | $1.1B | -12.14 | 13.65% | -185.71% | -28.77% | — |
Compare ABPWW vs Peers
Abpro Holdings Inc (ABPWW) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ABPWW SEC Filings & Documents
Abpro Holdings Inc (ABPWW) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ABPWW posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ABPWW Frequently Asked Questions
Abpro Holdings Inc (ABPWW) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
How fast is Abpro Holdings Inc growing?
Abpro Holdings Inc (ABPWW) saw revenue decline by 100.0% over the past year.
Is ABPWW profitable?
Abpro Holdings Inc (ABPWW) reported a net loss of $9.6M for fiscal year 2025.
Dividend & Returns
What is ABPWW's return on equity?
Abpro Holdings Inc (ABPWW) has a return on equity (ROE) of -526.8%. Negative ROE indicates the company is unprofitable.
What is Abpro Holdings Inc's free cash flow?
Abpro Holdings Inc (ABPWW) had negative free cash flow of $7.5M in fiscal year 2025, likely due to heavy capital investments.